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Objective: This review examines and summarizes the pharmacodynamic and pharmacokinetic 
properties, short- and longer-term efﬁ  cacy, the moderating effect of comorbid disorders, as well 
as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric 
attention-deﬁ  cit/hyperactivity disorder (ADHD).
Methods: A systematic literature search was performed to review the extant literature on 
articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or 
adolescent ADHD.
Results: There is an extensive literature on atomoxetine; over 4000 children have participated 
in clinical trials of atomoxetine, demonstrating its short- and longer-term efﬁ  cacy. In addition, 
studies have examined the moderating effect of comorbid disorders on atomoxetine response, as 
well as atomoxetine’s therapeutic potential for other psychiatric conditions. Short- and longer-
term safety and tolerability continue to be reported.
Conclusions: Atomoxetine is indicated for both acute and maintenance/extended treatment of 
pediatric ADHD. Clinicians and families must be familiar with atomoxetine’s evidence base, includ-
ing its proﬁ  le of clinical response and its possible effectiveness in the presence of comorbidity.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is the most common childhood 
neurobehavioral disorder in the United States with an estimated prevalence of 6% to 8%.1 
Both the American Academy of Pediatrics (AAP) and the American Academy of Child 
and Adolescent Psychiatry (AACAP) recommend either a stimulant or atomoxetine as 
psychopharmacological agents for its treatment.2,3 Atomoxetine (Strattera®; Eli Lilly and 
Company), a selective norepinephrine reuptake inhibitor (SNRI), is the only non-stimulant 
approved by the FDA for the treatment of ADHD in children, adolescents and adults. 
While stimulant class medications are frequently used as ﬁ  rst-line agents, atomoxetine 
may also be considered as an initial choice, particularly in the presence of select comorbid 
disorders, including active substance abuse, anxiety disorder or tic disorder.2
Here we aim to summarize the extensive literature on atomoxetine, including its 
pharmacodynamic and pharmacokinetic properties, short- and longer-term efﬁ  cacy, 
the moderating effect of comorbid disorders, as well as short- and long-term safety 
and tolerability. We will close with summary clinical recommendations for the use 
of atomoxetine in pediatric ADHD.
Pharmacodynamics
Atomoxetine is a potent norepinephrine (NE) uptake inhibitor in vitro and in vivo 
with relatively low afﬁ  nity for 5-HT and DA uptake sites;4,5 it has 290-fold lower Neuropsychiatric Disease and Treatment 2009:5 216
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afﬁ  nity for dopamine transporters than norepinephrine.6 
Mechanistically, inhibition of the NE transporter blocks 
synaptic clearance of NE, thereby increasing synaptic NE 
concentrations in noradrenergic pathways. For example, 
NE in prefrontal cortical (PFC) regions has been shown 
to play a key role in attention and higher cognitive 
processes.6
In animal studies, atomoxetine has been shown to selec-
tively increase dopamine (DA) to a similar magnitude as 
NE in the PFC, due to region-speciﬁ  c shared monoamine 
uptake inhibition, while not altering DA in other dopamine-
rich brain regions such as nucleus accumbens and striatum.6 
In addition, atomoxetine robustly increased NE in other 
brain regions with a substantial density of norepinephrine 
transporters; atomoxetine rapidly and persistently increased 
norepinephrine in rat occipital cortex, lateral hypothalamus, 
dorsal hippocampus, and cerebellum.7
Pharmacokinetics
Absorption and distribution
Atomoxetine is efﬁ  ciently absorbed after oral administration 
(range 63%–94%); its bioavailability is minimally affected 
by food. After oral administration, atomoxetine reaches a 
maximum plasma concentration in approximately 1 to 2 hours. 
Atomoxetine is highly protein bound, roughly 98%, speciﬁ  cally 
to albumin.8–10
Metabolism and elimination
There are three metabolic pathways involved in the clearance 
of atomoxetine; aromatic ring-hydroxylation, benzylic hydrox-
ylation, and N-demethylation. The hepatic enzyme cytochrome 
P450 2D6 (CYP2D6) is the primary metabolic pathway 
for atomoxetine, yielding its primary oxidative metabolite 
4-hydroxyatomoxetine.9,11 Over 80% of the atomoxetine dose 
is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide 
in the urine, with a minority excreted in the feces.12 It is well 
known that there are distinct differences within populations of 
CYP2D6 activity (extensive versus poor metabolizers), and that 
genetic tests are presently available to identify this variability. 
Those persons who are deemed “poor metabolizers” (PM) of 
CYP2D6 drugs (about 7% of the Caucasian population) have 
been shown to have mean peak atomoxetine concentrations 
up to 5-fold higher and total plasma exposure of atomoxetine 
10-fold higher than persons who have extensive (normal) 
metabolic (EM) activity.13 Atomoxetine has a plasma half-life 
of about 5.2 hours in extensive metabolizers,9,12 compared to 
22 hours in poor metabolizers, as atomoxetine is metabolized 
through several alternative CYP pathways.13 From a clinical 
standpoint, the important question is: what is the practical 
impact of CYP metabolism status on the treatment of a given 
patient? A recent pooled analysis addressed this question by 
examining the relationship between CYP2D6 status and clinical 
response in children and adolescents with ADHD.13 Efﬁ  cacy 
data were derived from 6 acute clinical trials (N = 559 EMs, 
30 PMs), while safety and tolerability data was assessed using 
a pooled database from 14 studies (N = 3017 EMs, 237 PMs). 
Efﬁ  cacy analyses demonstrated signiﬁ  cantly greater improve-
ments in ADHD rating scale scores and rates of response in 
PMs as compared to EMs (80% and 59% response rates in 
PMs and EMs respectively). However, the pooled efﬁ  cacy 
and PK data found a low (0.179) correlation coefﬁ  cient between 
response and peak concentration; the differential efﬁ  cacy 
between EMs and PMs may instead be related to total plasma 
atomoxetine exposure or area under the curve (AUC).13 In this 
same analysis, reduced appetite, insomnia and tremor were 
seen in signiﬁ  cantly greater rates in PMs, compared to EMs.13 
In addition, signiﬁ  cantly greater increases in mean pulse rate 
at endpoint (+3.9 bpm) and in mean diastolic blood pressure 
(DBP) at endpoint (+1.6 mmHg) were observed in PMs, as 
compared to EMs.13 The authors suggest that these differences 
may be due to increased noradrenergic tone in PM and/or due 
to persistent effects due to more constant drug concentrations 
throughout the day.
Since atomoxetine is highly protein bound, systemic 
clearance of atomoxetine may be signiﬁ  cantly reduced in 
those patients with hepatic impairment. Dosage adjustment 
is recommended in these patients.14
Efﬁ  cacy
Short-term atomoxetine treatment 
in children and adolescents
Pivotal studies of atomoxetine in pediatric ADHD ﬁ  rst 
emerged in 2001. Following a small open-label dose rang-
ing study,15 a large randomized controlled trial demonstrated 
superior efﬁ  cacy of 1.2 mg/kg/day and 1.8 mg/kg/day doses 
compared with placebo.16 This multicenter 8-week trial 
included 297 children and adolescents with ADHD. All 
subjects began with 0.5 mg/kg/day, in divided (twice daily) 
dosing, increased at weekly intervals. Efﬁ  cacy was mea-
sured using parent and investigator ADHD rating scales; the 
1.2 mg/kg and 1.8 mg/kg doses were signiﬁ  cantly superior to 
placebo at reducing ADHD symptoms, with similar improve-
ment for inattentive and hyperactive/impulsive subtype 
symptoms. Improvements in social and family functioning 
were also observed using a number of secondary outcome 
measures.Neuropsychiatric Disease and Treatment 2009:5 217
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The magnitude of improvement with atomoxetine treatment 
as judged by teachers has been found to be similar (effect 
size = 0.63) to that seen in studies based on investigator inter-
views with parents (0.6 and 0.8).17 This study, by Weiss et al17 
used the ADHD-RS-IV-Teacher:Inv as the primary outcome 
measure. This scale was completed by investigators during 
a 4-day period before each study visit, based on a telephone 
interview with the child’s primary teacher. Teachers reported 
improvement within 1 week of initiating therapy.
Overall, short-term ADHD symptom improvement has 
been demonstrated in multiple settings as assessed by clinician, 
parent, and teachers, and as measured according to a variety of 
outcomes over the short term. A recent meta-analysis reported 
the number-needed-to-treat (NNT) for atomoxetine treat-
ment response (reduction of 25% in ADHD-RS total score 
from baseline) was 3.43 (95% CI, 2.79–4.45).18 Signiﬁ  cant 
improvement compared with those treated with placebo has 
been demonstrated across efficacy measures, in younger 
(6–7 years) and older (8–12 years) children: ADHD-RS 
total score: younger ES = 0.77, older ES = 0.65; Inattentive 
subscale: younger ES = 0.71, older ES = 0.59; Hyperac-
tive/Impulsive subscale: younger ES = 0.76, older ES = 0.62; 
CGI-ADHD-S score: younger ES = 0.62, older ES = 0.59.19 
However, overall in the treatment of pediatric ADHD, superior 
effect sizes are consistently observed with immediate-release 
and long-acting stimulants, as compared to non-stimulants, 
including atomoxetine.20
When does clinical response occur?
The full efficacy of atomoxetine may not be seen in 
short-term treatment studies. In two very short-term 
(3-week) open-label studies with OROS methylphenidate21 
and mixed amphetamine salts extended release (MAS XR) 
comparators,22 each stimulant medication demonstrated 
superior effectiveness over atomoxetine, while a 10-week 
study by Kratochvil et al23 reported similar effectiveness 
with either atomoxetine or immediate-release methylpheni-
date. A gradual clinical response to atomoxetine is depicted 
in the report by Wilens et al; in a large sample (N = 882) of 
adolescents, mean ADHD-RS score continued to decline 
up until the 3rd month of treatment, at which point scores 
stabilized and remained so, over 24 months of treatment.24 
Thus, patience with this medication may be necessary in 
order to appreciate its full efﬁ  cacy.
Does dosing matter?
In theory, twice daily dosing may provide greater efﬁ  cacy 
with more consistent plasma atomoxetine exposure, consistent 
with PK ﬁ  ndings.13 However, several trials have demonstrated 
that atomoxetine appears to be as effective when the dose is 
given as a single daily dose.17,25,26 In the latter study,26 which 
used a more rapid early dose titration schedule, statistically 
signiﬁ  cant improvement was observed after 1 week of treat-
ment, with evidence for superior efﬁ  cacy, compared with 
placebo, as soon as the ﬁ  rst day of treatment, according to 
daily analyses of parent ratings.
For example, Kelsey et al26 reported on a large group 
of children receiving 8 weeks of once daily atomoxetine or 
placebo. Atomoxetine titration was relatively rapid, begin-
ning at 0.8 mg/kg/day for 3 days, increasing to 1.2 mg/kg/day 
for 4 weeks, with the option to increase to 1.8 mg/kg/day 
according to tolerability and clinical assessment. Using a 
novel instrument, parents rated children’s behaviors in the 
morning (before AM dosing and representing trough levels) 
and evening (after 6 PM), such as getting up, doing home-
work, and sitting through dinner. Parents recorded observa-
tions using an electronic entry system to record on a daily 
diary. Total score, as well as evening and morning subscales 
showed statistically signiﬁ  cant improvements from baseline 
to endpoint. Comparisons of mean changes in individual 
parent ratings demonstrated signiﬁ  cant atomoxetine-speciﬁ  c 
reductions for 5 of 8 evening items and 2 of the 3 morning 
items. Results obtained with a validated scale assessing 
evening behaviors (Conners’ GIPE) also showed statisti-
cally signiﬁ  cant improvements in total score for evening 
behaviors from baseline to endpoint. The treatment effect 
size in this study for the primary outcome measure was 0.7, 
compared with 0.8, 0.7, and 0.6 in the studies of twice-daily 
atomoxetine.26
What about atomoxetine response 
in children previously treated 
with stimulants?
In a unique crossover design, Newcorn et al27 reported on the 
response to atomoxetine in children who had been previously 
treated with stimulant medication. Youth with ADHD, any sub-
type, were randomly assigned to receive 0.8 to 1.8 mg/kg/day 
of atomoxetine (N = 222), 18 to 54 mg/day of OROS MPH 
(N = 220), or placebo (N = 74) for 6 weeks. For youth with 
a history of stimulant treatment (N = 301), the response rate 
for atomoxetine was 37%, as compared to the 57% response 
rate observed in patients who were stimulant naive at study 
entry (N = 191). Meta-analysis demonstrating the short-term 
efﬁ  cacy of atomoxetine in children and adolescents includes 
high rates of children (57%) and adolescents (75%) with prior 
stimulant exposure.24Neuropsychiatric Disease and Treatment 2009:5 218
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Special populations: children with poor 
prior stimulant response
The Newcorn et al27 trial is the only large, controlled study to 
offer within-subject data (crossover) characterizing treatment 
response to atomoxetine in children who did not respond to 
stimulant treatment during the study itself ( 40% decrease 
in ADHD rating scale). After 6 weeks of initial treatment, 
under double blinded conditions, children treated with OROS 
MPH were switched to atomoxetine. For the 70 youths who 
did not respond to OROS MPH in the trial, 43% subsequently 
responded to atomoxetine.
Overall, despite limitations noted by the authors (eg, no 
washout period between the two treatments), there are helpful 
clinical ﬁ  ndings in this novel study. About one-half of sub-
jects who switched to atomoxetine after completing 6 weeks 
of methylphenidate responded robustly to both treatments. 
Yet, the majority of the others responded preferentially to one 
treatment, either methylphenidate or atomoxetine. A sizeable 
smaller number (22%) were non-responders to both meth-
ylphenidate and atomoxetine. Differential response may 
be due to pharmacologic, metabolic and pharmacokinetic 
differences at an individual level.
There are two previous studies in which children were a 
priori selected for atomoxetine treatment based upon incom-
plete response or intolerance to prior stimulant treatment.28,29 
In the Quintana et al28 study, signiﬁ  cant mean reductions in 
ADHD-RS Parent:Inv total scores were observed from base-
line to end point (32.1 vs 22.6; p  0.001). However, this 
study was limited by a stepwise cross titration, with ongoing 
stimulant treatment during the ﬁ  rst 2 weeks of atomoxetine 
treatment.
Hammerness et al29 conducted a prospective short-term, 
open-label study of atomoxetine in the treatment of youth 
with ADHD who had been non-responsive and/or had a his-
tory of poor stimulant tolerability. In this study, atomoxetine 
monotherapy (doses of up to 1.4 mg/kg/day) was associated 
with signiﬁ  cant reductions in ADHD symptomatology and 
signiﬁ  cant overall global improvement (CGI-I ADHD). The 
magnitude of response to atomoxetine (53% with 30% reduc-
tion in ADHD-RS; 41% with 50% reduction) was consistent 
with previous controlled clinical trials of atomoxetine in 
pediatric ADHD.16
Special populations: young children
Kratochivil et al30 recently reported on the safety and 
effectiveness of atomoxetine in an open-label study with 
22 subjects, ages 5 to 6. The mean ﬁ  nal dose was 1.25 mg/kg/day. 
Comparable efﬁ  cacy to older age groups was observed, with 
a mean decrease of 21 ADHD-IV RS total points (SD = 12.8, 
p  0.001). Similar mean decreases of 10 points (SD = 7.48, 
p  0.001) on the inattentive subscale, and 11 points 
(SD = 7.04, p  0.001) on the hyperactive/impulsive subscale 
were reported.
Can atomoxetine be combined 
with stimulants?
Due to the presence of residual ADHD symptoms following 
primary treatment, adverse effects or psychiatric comorbidity, 
clinicians commonly utilize a combination of medications 
for youth with ADHD.31 Two recent studies examined the 
combination treatment of atomoxetine and stimulant.32,33 
Carlson et al32 took a small group of children who did not 
initially respond to 4 weeks of atomoxetine and randomized 
them to atomoxetine + OROS MPH (N = 9) or atomoxetine + 
placebo (N = 12) for an additional 6 weeks. There were no 
signiﬁ  cant differences between groups; however the small 
sample size and the use of subjects who were resistant to 
previous stimulant trials and retested on MPH limits the 
ﬁ  nding.
Wilens et al33 conducted a similar design, 2-phase, 
7-week open study in children aged 6 to 17 years. However, 
children were not selected based upon prior lack of response 
to stimulant treatment. After monotherapy with atomoxetine 
for 4 weeks, partial responders to atomoxetine added OROS 
MPH (titrated to 54 mg over a subsequent 3 weeks) to their 
regimen. Subjects were assessed on multiple outcomes 
including ADHD, executive functioning and adverse effects. 
Of fifty subjects treated with the combination therapy, 
41 subjects completed the entire protocol. There was a 40% 
reduction in their ADHD-RS from the beginning of combi-
nation treatment through the end of study (from 21.14 ± 9.9 
to 12.8 ± 9.7, t = 6.5, p  0.0001). In addition, there was a 
clinically signiﬁ  cant reduction in the Clinical Global Index 
of ADHD severity from moderate to mild ADHD as well 
as improvements in executive functioning.33 Hammerness 
et al29 reported the tolerability of this combined regimen; 
compared to atomoxetine alone, adjunct OROS MPH was 
associated with signiﬁ  cantly greater rates of insomnia, irri-
tability, and loss of appetite.
Longer-term atomoxetine: is efﬁ  cacy 
maintained?
The beneﬁ  t of maintaining pediatric patients (ages 6–15 years) 
with ADHD on atomoxetine has been demonstrated in con-
trolled studies, allowing for atomoxetine to receive the unique 
indication for both acute and maintenance/extended treatment Neuropsychiatric Disease and Treatment 2009:5 219
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of ADHD. However, according to current prescribing 
information, the long-term usefulness of atomoxetine for 
an individual patient should periodically be re-evaluated 
over extended treatment periods (Lilly, Product Informa-
tion, Sept 2008).
In recent meta-analyses of controlled and open-label stud-
ies, the maintenance of efﬁ  cacy (according to ADHD-RS-IV-
Parent:lnv) is demonstrated over 2 years; 25.7% of children,34 
and 16.5% of adolescents discontinued due to lack of effective-
ness over the study period.24 Similarly, in the Spencer et al35 
report documenting safety of 5-year maintenance, only 16% 
discontinued due to lack of efﬁ  cacy.
Atomoxetine maintenance has also been studied in 
children and adolescents in a naturalistic setting. A recent 
observational open-label study of patients (N = 627; mean 
age = 11 years) with ADHD involved children treated at 
60 physicians’ ofﬁ  ces across the United States and Puerto 
Rico.36 Physicians were prescribed atomoxetine either as 
initial treatment or after trying another ADHD treatment 
(eg, stimulants, antidepressants). Atomoxetine administra-
tion, dosing, and timing of follow-up visits occurred at each 
physician’s discretion. Treatment length ranged from 0 to 
89 weeks with an average span of 21.2 weeks. The primary 
measure of efﬁ  cacy was the Physician Global Impression: 
ADHD Severity (PGI-ADHD-S) scale, which had a mean 
severity decrease of 0.91 (95% CI: –1.00 to –0.82, p  0.001). 
Fifty-nine to 69% of subjects demonstrated consistent control 
of ADHD symptoms throughout the day, with improvement 
in subjects’ grades reported by teachers, and improvement 
in subjects’ behavior reported by parents.
Is there evidence of relapse 
after atomoxetine is stopped?
A unique study by Michelson et al37 examined relapse in 
a large pediatric sample derived from 33 academic investiga-
tive centers in Europe, Israel, South Africa, and Australia. The 
study included children and adolescents who had previously 
participated in a 12-week open-label atomoxetine treatment.38 
Of the original 416 subjects, 163 (26%) completed 1 year 
of treatment with atomoxetine and were re-randomized to 
6 additional months of treatment with atomoxetine (n = 81) 
or placebo (n = 82). Subject worsening of symptoms (deﬁ  ned 
as symptom severity returning to 50% of baseline) was 
signiﬁ  cantly greater in those switched to placebo (47.6%), 
than those who remained on atomoxetine (28.4%). Buitelaar 
et al’s39 report extends these results; after 1 year, 42% of those 
in the placebo group would be classiﬁ  ed as relapsers (increase 
in ADHD-RS total score to 1.5 standard deviations above 
norm) compared with 22% of atomoxetine-treated subjects 
(p = 0.010).
Efﬁ  cacy – comorbid conditions
Up to 60% of children with ADHD suffer from psychiatric 
comorbidity, including oppositional deﬁ  ant disorder (ODD), 
anxiety and mood disorders, tic disorders, and pervasive 
development disorder (PDD).
Oppositional deﬁ  ant disorder
The most common co-morbid condition of ADHD is ODD, 
which occurs in 40% to 60% of children with ADHD.40 
However, the methodology and patient population selected to 
study atomoxetine response in ODD has varied considerably. 
The recent meta-analysis on this topic40 identiﬁ  es some of 
these limitations; differences in inclusion criteria eg, subject 
ages (inclusion or exclusion of adolescents), study duration 
(6, 7, or 8 weeks of exposure), diagnostic entry criteria (1.0 vs 
1.5 standard deviations above the norm).
Does atomoxetine work in children 
with ADHD and ODD/ODD symptoms?
In a recent report, Biederman et al40 examined whether 
comorbid ODD impacted response to atomoxetine in chil-
dren with ADHD. Acute-phase data were analyzed from 
three randomized, double-blind, placebo-controlled studies 
in children aged 6 to 16 with ADHD conducted in the USA 
and Canada.17,25,26 Subjects received placebo or atomoxetine 
(max 1.8 mg/kg/day) for 6 to 8 weeks. In this large sample, 
158/512 were diagnosed with comorbid ODD. Relative to 
placebo, atomoxetine treatment signiﬁ  cantly reduced ADHD 
symptoms in both ODD-comorbid and non-comorbid sub-
jects, indicating that the presence of comorbid ODD did 
not affect ADHD treatment response. ADHD subjects also 
showed signiﬁ  cant improvements from baseline on most of 
the psychosocial measures of the child health questionnaire 
regardless of the comorbidity with ODD.
Other reports have found greater efﬁ  cacy in treating 
comorbid ADHD + ODD at higher dosing; in the Newcorn 
et al41 study, the comorbid group showed improvement com-
pared with placebo at 1.8 mg/kg/day but not 1.2 mg/kg/day. 
However, Newcorn et al’s41 ﬁ  ndings have not been found 
by others.40
In one longer-term study, Hazell et al42 examined the 
inﬂ  uence of comorbid ODD on the relative risk (RR) of 
relapse during 9 months of treatment with atomoxetine 
for ADHD; fewer youth with comorbid ODD relapsed 
during maintenance atomoxetine treatment, as compared Neuropsychiatric Disease and Treatment 2009:5 220
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to youth without comorbid ODD (17% vs 26%; RR 0.67, 
95% CI 0.42–1.06).
Is atomoxetine effective in reducing 
ODD symptoms?
In examinations of data from positive randomized clinical 
trials of atomoxetine in pediatric ADHD,43 investigators 
have not observed signiﬁ  cant decreases in ODD rating scale 
scores in atomoxetine treated children compared to placebo; 
CPRS-R:S Oppositional subscore.44 Consistent with this 
analysis, Biederman et al40 found no signiﬁ  cant treatment 
difference in the CPRS-R:S oppositional subscale change 
scores; reduction in ODD symptoms was highly related 
to the magnitude of ADHD response. One study which 
demonstrated statistically signiﬁ  cant improvement in ODD 
may have beneﬁ  ted from twice-daily dosing, allowing for 
better control of oppositional symptoms during the evening 
hours.41 A recent placebo controlled trial of ADHD and ODD 
found signiﬁ  cant improvement for ADHD symptoms but 
not for ODD symptoms at endpoint analysis.45 In this study, 
the investigator-rated Swanson, Nolan, and Pelham Rating 
Scale-Revised (SNAP-R) was used to determine treatment 
effect on ODD and ADHD symptoms.
Pervasive developmental disorders
Several small, short-term studies have examined the eff icacy 
and tolerability of atomoxetine in children with PDD and 
ADHD symptoms. One trial with a crossover design examined 
atomoxetine and placebo response during 6 week periods, sepa-
rated by a one week washout.46 Twelve boys and 4 girls (7 with 
autistic disorder, 1 Asperger’s, 8 pervasive developmental dis-
order not otherwise speciﬁ  ed) all completed at least 3 weeks of 
each treatment condition. On the primary outcome, the Hyper-
activity subscale of the Aberrant Behavior Checklist, atomox-
etine was superior to placebo (p = 0.043, effect size d = 0.90). 
In this study, atomoxetine demonstrated signiﬁ  cant eff icacy 
in reducing core DSM-IV ADHD hyperactive/impulsive 
symptoms (p = 0.005, d = 1.27), but not inattentive symptoms 
(p = 0.053, d = 0.89). While atomoxetine was generally well 
tolerated, with no tendency to stereotypy, one participant was 
re-hospitalized for recurrent violence on atomoxetine. Similar 
effectiveness in aberrant behavior (hyperactivity subscale 
only) has been observed in a longer (10 week) trial, although 
still based upon an open trial with a small sample.47 Improve-
ments have also been reported in irritability, social withdrawal, 
stereotypy, and repetitive speech.48
Tolerability may be an area to watch in this patient popu-
lation; in one study, 5 patients (42%) discontinued because of 
side effects, including gastrointestinal symptoms, irritability, 
sleep problems, and fatigue.47 Although again, conclusions 
based on these ﬁ  ndings cannot be made due to the very small 
sample size.
Tic disorders
Given that stimulant medications have been associated with 
the onset or exacerbation of a tic disorder, atomoxetine may 
offer unique efﬁ  cacy and/or tolerability in children with 
ADHD and comorbid tic disorders; Tourette’s syndrome 
(TS), and/or simple motor tic disorder. In the largest study 
to date, Allen et al49 examined children (7–17 years) with 
ADHD and concurrent TS or chronic motor tic disorder in 
a double-blind randomized treatment study with placebo 
(n = 72) or atomoxetine (0.5–1.5 mg/kg/day, n = 76) for 
up to 18 weeks. Atomoxetine was associated with a greater 
reduction of tic severity at endpoint relative to placebo 
on the Clinical Global Impressions (CGI) tic/neurologic 
severity scale score (−0.7 ± 1.2 vs −0.1 ± 1.0, p = 0.002); 
however signiﬁ  cance was not reached in Yale Global Tic 
Severity Scale (YGTSS) total score, nor the Tic Symptom 
Self-Report total score. In a subset of this study that included 
only children with comorbid TS, atomoxetine was associated 
with signiﬁ  cant reduction of tic severity on two of three 
measures.35
Childhood anxiety disorders
In addition to comorbid ODD and tics, approximately 
one third of children with ADHD have comorbid anxiety 
disorders. The one large controlled study of ADHD and 
comorbid anxiety was published this past year. In this trial, 
Geller et al50 enrolled 176 children (ages 8–17 years) who 
met DSM-IV criteria for ADHD and generalized anxiety 
disorder, separation anxiety disorder, and/or social phobia. 
Children were randomized to 12 weeks of atomoxetine 
(n = 87) or placebo (n = 89). Sixty-six patients in each 
group completed the study. Mean ADHD-RS-IV-Parent:
Inv total score improved significantly for atomoxetine 
(n = 55; −10.5, SD 10.6) relative to placebo (n = 58; –1.4, 
SD 8.3; p  0.001; ES = 0.84). Mean Pediatric Anxiety 
Rating Scale (PARS) total score also improved signiﬁ  cantly 
for atomoxetine (n = 55; −5.5, SD 4.8) relative to placebo 
(n = 58; −3.2, SD 5.0; p = 0.011). There was also a signiﬁ  cant 
reduction in independently assessed anxiety symptoms using 
both clinician-rated and self-rated measures.
In comparison, a study by Abikoff et al51 involved the 
sequential treatment of children with ADHD and anxiety 
using ﬂuvoxamine. While children with ADHD and anxiety Neuropsychiatric Disease and Treatment 2009:5 221
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were found to have a response rate to stimulants for ADHD 
that is comparable with that of children with general ADHD, 
subsequent blinded assignment to 8 weeks of ﬂ  uvoxamine 
treatment was not found to be statistically superior to pla-
cebo, based on the Pediatric Anxiety Rating Scale or Clinical 
Global Impressions-Improvement.
Childhood mood disorders
Affective disorders occur at elevated rates in ADHD, and the 
management of comorbid depressed or irritable/explosive in 
the context of ADHD represents a particularly difﬁ  cult clinical 
challenge. One study to date has examined atomoxetine in 
adolescents with ADHD and comorbid major depressive 
disorder (MDD).52 Patients were treated for approximately 
9 weeks with atomoxetine (1.8 mg/kg per day) (n = 72) or 
placebo (n = 70). While atomoxetine was effective in signiﬁ  -
cantly reducing ADHD symptoms in this depressed sample, 
Children’s Depression Rating Scale-Revised (CDRS-R) 
score improvement was not signiﬁ  cantly different between 
groups (atomoxetine, −14.8 ± 13.3; placebo, –12.8 ± 10.4). 
Rates of treatment-emergent mania did not differ between 
groups (atomoxetine, 0.0%; placebo, 1.5%) nor was there 
spontaneously reported adverse events involving suicidal 
ideation or suicidal behavior in either group.
In an earlier study by Kratochvil et al53 patients with 
ADHD and concurrent symptoms of depression or anxiety 
were randomized to treatment with ﬂuoxetine (n = 127) or 
placebo (n = 46) under double-blind conditions for 8 weeks, 
with concomitant atomoxetine during the last 5 weeks. Depres-
sive symptom reductions according to the CDRS-R were not 
different between groups. Yet, interestingly, improvement in 
CDRS-R was signiﬁ  cantly greater in subjects with the highest 
atomoxetine serum levels.
There are limited data to guide the clinician in the 
management of bipolar disorder (BD) and ADHD. Hah and 
Chang54 reported a consecutive case series on 7 patients with 
pediatric BD and ADHD who were treated with atomoxetine. 
The majority (6) of patients were treated concurrently with 
mood stabilizers. All but 1 patient demonstrated signiﬁ  cant 
improvement in symptoms of ADHD. No patients had 
episodes of hypomania or mania during the treatment 
period.
Tolerability
General tolerability
Atomoxetine is generally well tolerated in healthy children 
and adolescents, with mild adverse effects. Based on data 
from 6 acute treatment clinical trials (6–9 weeks’ duration) 
involving 280 younger children ages 6 to 7 years, and 
860 older subjects, ages 8 to 12 years, younger children 
had signiﬁ  cantly higher rates of upper abdominal pain, 
decreased appetite, vomiting, and somnolence (atomoxetine 
versus placebo [PBO]). Among older children, there were 
signiﬁ  cantly higher rates of decreased appetite, somno-
lence, irritability, and fatigue observed for those taking 
atomoxetine versus PBO.19 In this review, a signiﬁ  cant treat-
ment-by-age-group interaction was observed for abdominal 
pain (younger: atomoxetine = 19%, PBO = 6%; older: 
atomoxetine = 15%, PBO = 13%; p = 0.044), and vomiting 
(younger: atomoxetine = 14%, PBO = 2%; older: atomoxetine 
= 9%, PBO = 6%; p = 0.053).19 No new or unexpected safety 
concerns have been reported over longer-term treatment.24
Enhancing general tolerability; titration, 
and dosing
Data on atomoxetine treatment and the emergence of adverse 
events has shown that the frequency of adverse events may 
depend on method of drug initiation. During initiation of 
therapy, patients rapidly titrating to 1.2 mg/kg/day over 
3 days, as a single daily dose, reported higher rates of spon-
taneous adverse events than patients on a twice-daily dos-
ing with gradual titration over 3 weeks.55 Clinically, some 
children may tolerate a divided dose well during initiation 
of treatment, and then be able to switch over to a once-daily 
dosing schedule for maintenance.
Atomoxetine and growth
In a 5-year safety of treatment study, Spencer et al35 reported 
on the impact of atomoxetine on growth in a large sample of 
children and adolescent participants. Maximum decrement 
of weight loss was observed at 15 months (−9.9% percent-
age points; p  0.001); however by the 5-year time point, 
subjects had slightly overshot their starting weight percentile. 
Similarly, maximum decrement from expected height was 
observed at 18 mos (−6.6% percentage points; p  0.001). 
The impact of ADHD pharmacotherapy on growth is an area 
of ongoing research, including studies of stimulant class and 
non-stimulant medications, and the consideration of moderat-
ing impact of age. However, at present, continuous atomox-
etine treatment does not appear to have signiﬁ  cant effect on 
juvenile growth and ﬁ  nal stature for most patients.35
Atomoxetine and suicidality
The following boxed warning has been placed (July, 2008) 
into the package insert for atomoxetine: “Atomoxetine 
increased the risk of suicidal ideation in short-term studies in Neuropsychiatric Disease and Treatment 2009:5 222
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children or adolescents with Attention-Deﬁ  cit/Hyperactivity 
Disorder (ADHD). Pooled analyses of short-term (6–18 weeks) 
placebo-controlled trials of STRATTERA in children and 
adolescents (a total of 12 trials involving over 2200 patients, 
including 11 trials in ADHD and 1 trial in enuresis) have 
revealed a greater risk of suicidal ideation early during treat-
ment in those receiving STRATTERA compared to placebo. 
The average risk of suicidal ideation in patients receiving 
STRATTERA was 0.4% (5/1357 patients), compared to none 
in placebo-treated patients (851 patients). No suicides occurred 
in these trials.”
In a meta-analysis of 14 trials on suicide-related behavior 
in pediatric patients treated with study drug, placebo, or 
methylphenidate, no ADHD patients being treated with 
atomoxetine committed suicide.45 The frequency of suicidal 
ideation in patients taking atomoxetine was 0.37% vs 0% 
in a placebo group. Frequencies between atomoxetine and 
methylphenidate groups did not differ.45
In sum, there is no current evidence that atomoxetine 
causes suicide in youth. However, consistent with FDA 
recommendations, clinicians should consider the impact 
of psychiatric comorbidity, which may be associated with 
suicidal ideation and/or suicidal behavior. Clinicians should 
inquire about personal or family histories of mood disorders, 
as well as clarify whether suicidality has been present before 
starting atomoxetine. As part of monitoring, clinicians can 
then inquire about any (negative) changes in mood during 
treatment, eg, depression, agitation, or worsening of frustra-
tion tolerance (in contrast to effective ADHD treatment in 
which parents will often comment on improved mood, noting 
that the child is less reactive, irritable or easily frustrated).
Atomoxetine and aggression/psychosis
In a meta-analysis of aggression/hostility-related events from 
14 trials of atomoxetine, aggression/hostility-related events 
occurred in less than 2% of patients and were more frequent 
in pediatric patients treated with atomoxetine versus placebo 
(risk ratio of 1.33; not statistically signiﬁ  cant). The risk of 
aggression/hostility events was similar in patients treated with 
atomoxetine or methylphenidate.56 In a pooled analysis of 
multiple short-term, placebo-controlled studies, such symptoms 
occurred in about 0.2% (4 patients with reactions out of 1939 
exposed to atomoxetine for several weeks at usual doses) of 
atomoxetine-treated patients compared to 0 out of 1056 pla-
cebo-treated patients (Lilly, Product Information, July 2008).
As per the current FDA medication guide, while rare, 
treatment emergent psychotic or manic symptoms may 
occur. Therefore, the same principles as described above 
apply; clinicians should inquire about personal or family 
histories of mood disorders and psychosis prior to initiation of 
atomoxetine. If mood changes occur, inquiry about additional 
symptoms such as pressured speech, and decreased need for 
sleep may assist in identifying irritability associated with 
mania/bipolar disorder, from irritability, which may be more 
consistent with ﬂ  uctuating levels of oppositionality.
Atomoxetine and hepatic injury
There have been rare reports of hepatic injury associated with 
atomoxetine. In an investigation of case reports identiﬁ  ed 
by a computerized search that contained potential hepatic 
events, of the 7962 pediatric and adult patients treated with 
atomoxetine in clinical trials, 41 were identiﬁ  ed as requir-
ing further analysis. Of those 41 cases, none progressed to 
liver failure, and most of these events were mild increases 
in aminotransferase (ALT) and aspartate aminotrasferase 
(AST) levels.45 During the 4 years after the market launch of 
atomoxetine, 351 cases of liver injury were related to the drug 
treatment for ADHD. Of those 351 cases, 69 had explanations 
unrelated to the use of the drug, 146 presented insufﬁ  cient 
information to assess the cause, 133 contained confounding 
factors and were labeled as possibly related to drug use, and 
the remaining 3 cases reported liver injury probably related to 
atomoxetine use.45 The etiology of drug-induced liver injury 
with atomoxetine may be metabolic idiosyncrasy or induced 
autoimmune hepatitis.57
Given the rare nature of these reports, it is not currently 
recommended for clinicians to do routine monitoring of liver 
function tests during treatment, however, families should 
inform clinicians if they ﬁ  nd evidence of liver problems; 
itching, right upper belly pain, dark urine, yellow skin or 
eyes, or unexplained ﬂ  u-like symptoms (Lilly, Product 
Information, July 2008).
Atomoxetine and the cardiovascular 
system
There is no current evidence that treatment with therapeutic 
doses of ADHD pharmacotherapies in healthy children causes 
serious cardiovascular effects or sudden death.58 However, 
sudden death has been reported in association with atomox-
etine treatment at usual doses in children and adolescents with 
structural cardiac abnormalities or other serious heart prob-
lems. Although some serious heart problems alone carry an 
increased risk of sudden death, atomoxetine generally should 
not be used in children or adolescents with known serious 
structural cardiac abnormalities, cardiomyopathy, and serious 
heart rhythm (Lilly, Production Information, 2008).Neuropsychiatric Disease and Treatment 2009:5 223
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Children who are being considered for treatment with 
atomoxetine should have a careful clinical history (including 
assessment for a family history of early sudden death) and 
physical exam to assess for the presence of cardiac disease, 
as well as inquiring about possible cardiac symptoms includ-
ing chest pain and syncope. Electrocardiogram (ECG) is not 
a mandatory component of cardiovascular assessment and 
monitoring before and during ADHD pharmacotherapy.58,59
It is well documented that atomoxetine may increase heart 
rate in both younger (atomoxetine, 8.7 bpm [12.7]; PBO, 1.0 
(13.7); p = 0.001) and older (atomoxetine, 6.8 bpm [11.7]; 
PBO, 0.6 [11.3]; p  0.001) children. A statistically signiﬁ  cant 
treatment-group difference in systolic blood pressure (atom-
oxetine, 2.1 [9.8] mmHg; PBO, 0.3 [8.1] mmHg; p = 0.034) 
and diastolic blood pressure (atomoxetine, 2.9 [8.2] mmHg; 
PBO, 0.6 [8.0] mmHg; p = 0.002) has been observed for older 
children, but not for younger children.19
According to the current FDA medication guide, pulse 
and blood pressure should be measured at baseline, and 
periodically while on therapy. Such vigilance may identify 
certain children at heightened risk. For example, based upon 
pooled safety data, signiﬁ  cantly greater increases in mean 
pulse rate at endpoint (+3.9 bpm) and in mean diastolic 
blood pressure (DBP) at endpoint (+1.6 mmHg) have been 
observed in PMs, as compared to EMs.13 In addition, outliers 
(2.5% in pediatric placebo controlled trials) have been 
identiﬁ  ed, with HR increases 25 bpm; 1.1% had increases 
in HR of this magnitude on more than one occasion (Lilly, 
Product Information, July 2008). Signiﬁ  cant deviations 
from baseline vital signs and/or blood pressure in the 
pre-hypertension or hypertension range can be reviewed 
with the child’s primary care clinician and specialists in 
pediatric hypertension.
Atomoxetine and CNS toxicity
The rate of seizures as an adverse event with atomoxetine use 
has been estimated at between 0.1 and 0.2%.60 Post-market 
reports of seizure events were deemed as having no clear 
contributing or confounding factors, and the rate of report 
was within the normal population occurrences.60
Atomoxetine and overdose
Several studies have examined what happens when a child or 
adolescent is exposed to an overdose of atomoxetine, based 
upon poison center reports.61–64 Doses to 6.25 mg/kg,61 to 
249 ± 326 mg,62 and to 1200 mg63 have been reported. In some 
reports, adverse drug reactions did not correlate with atomox-
etine dose.61 In others, higher rates of serious outcome were 
found with greater maximum dose; 2.8 mg/kg or 200 mg 
or 4 tablets.64 No major outcomes or fatalities have been 
reported.62,63
However, exposures have caused GI upset, lethargy61–63 
and seizures in one child,62 and seizures in one adolescent 
female who ingested 2840 mg of atomoxetine in a suicide 
attempt; serum atomoxetine level of 1995 ng/mL.65 
Cardiovascular sequela has included sinus tachycardia, and 
increased blood pressure.61–63 Mood adverse effects include 
agitation;61 in one study, 17% had acute agitation and were 
treated with benzodiazepines.63 Despite this apparent safety 
proﬁ  le, clinicians should discuss with the patient and family 
members the importance of taking the atomoxetine doses 
as prescribed and appropriate monitoring of medications in 
the home.
Drug–drug interactions
Based upon preclinical data, atomoxetine is metabolized 
by CYP2D6, but does not induce or inhibit it.13 However, 
CYP2D6 inhibitors may reduce atomoxetine clearance; 
ﬂ  uoxetine, paroxetine, and quinidine, all drugs that inhibit 
CYP2D6, cause higher peak plasma concentrations and 
slower elimination.9 Thus, these CYP2D6 inhibitors may 
create an iatrogenic virtual PM phenotype in patients with 
an EM genotype.13
Atomoxetine should not be used within 2 weeks after 
discontinuing MAOI or other drugs that affect brain mono-
amine concentrations. Atomoxetine should be prescribed 
with caution if a patient is taking asthma (albuterol or other 
beta2 agonists), or other medications which could potenti-
ate pressor effects. In addition, there are a few case reports 
of neurological adverse events when atomoxetine is taken 
with other drugs; neck-facial twitches/tics with concurrent 
citalopram,66 venlafaxine,67 involuntary movements with 
a stimulant.67 In these cases, symptoms resolved after the 
discontinuation of atomoxetine and other medications.
Summary
Atomoxetine is indicated for both acute and maintenance/
extended treatment of pediatric ADHD. There is extensive 
literature on atomoxetine, documenting its pharmacodynamic 
and pharmacokinetic properties, as well as its short- and 
longer-term efﬁ  cacy, the moderating effect of comorbid 
disorders, and analyses of short- and long-term safety and 
tolerability. Overall, more children and adolescents have 
been studied in acute and long-term prospective studies with 
atomoxetine than with any other pediatric psychotropic in 
history. To date, over 4000 children have participated in Neuropsychiatric Disease and Treatment 2009:5 224
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clinical trials of atomoxetine, including 7 pediatric trials, of 
which 6 were a randomized, double-blind, placebo-controlled 
design.19,68
Clinicians and families should be well informed in regards 
to this evidence base, including the potential for a different 
proﬁ  le of clinical response, as compared to stimulant class 
medications. Atomoxetine’s full effects may accrue over 
months not weeks, and thus patience is necessary in prescrib-
ing and administering this medication. We can now point 
to controlled data demonstrating a near 50% atomoxetine 
response in children who recently failed a stimulant trial.
While atomoxetine has an overall effect size lower than 
the ﬁ  rst line stimulant class medications in short-term studies, 
it may be a better drug for an individual child. Given positive 
preliminary data in some of the more challenging comorbid 
conditions that occur in children with ADHD (ODD, tics, 
anxiety and mood disorders, PDD), atomoxetine’s role in 
these more complex patients may continue to emerge.
Finally, the FDA has recommended the development of medi-
cation guides, now available for all ADHD pharmacotherapeutic 
agents, including atomoxetine. Clinicians and families should 
be familiar with the latest recommendations and consensus, 
particularly as they apply to areas of cardiovascular safety and 
the monitoring of mood/behavioral changes and suicidality. The 
medication guide for atomoxetine can be found at http://www.
fda.gov/cder/Ofﬁ  ces/MG/atomoxetineMG/pdf. Consistent with 
current clinical consensus that ADHD is a chronic disorder, 
with impairment into adulthood, further research is warranted, 
to examine the efﬁ  cacy and safety of atomoxetine over extended 
periods of time.
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